Daiichi Sankyo Reports Pooled Analysis from TROPION-Lung05 & TROPION-Lung01 Trials of Datopotamab Deruxtecan (Dato-DXd) for NSCLC
Shots:
- Daiichi Sankyo reported pooled analysis from P-II (TROPION-Lung05, n=78) trial of Dato-DXd in patients progressed on at least one TKI therapy & P-III (TROPION-Lung01, n=39) study of Dato-DXd vs docetaxel to treat advanced or metastatic EGFRm NSCLC, with data featured at ESMO Asia 2024. BLA is based on this data across the US
- The pooled analysis showed confirmed ORR of 42.7% (CR: 4.3%, PR: 38.5%, SD: 41%), DCR of 86.3%, mDoR of 7mos., mPFS of 5.8mos. & mOS of 15.6mos.
- This pooled data was comparable with the outcomes in patients (n=96) treated with osimertinib, depicting confirmed ORR of 44.8% (CR: 4.2%, PR: 40.6%, SD: 38.5%), DCR of 85.4%, mDoR of 6.9mos., mPFS of 5.7mos. & mOS of 14.7mos.
Ref: Daiichi Sankyo | Image: Daiichi Sankyo
Related News:- Alteogen and Daiichi Sankyo Partner to Develop and Commercialize SC Formulation of Enhertu
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
